Patients with COVID-19 and HBV Coinfection are at Risk of Poor Prognosis.

ABSTRACT:

Introduction

This study aimed to determine whether there is a difference in the risk of death/critical illness between different stages of hepatitis B virus (HBV) (resolved hepatitis B, HBeAg (-) chronic hepatitis B [CHB]/infection, HBeAg (+) CHB/infection, and HBV reactivation) coinfected with coronavirus disease 2019 (COVID-19); and if there is a difference, whether it is due to abnormal liver function and to what extent.

Methods

This cohort study included all COVID-19 inpatients of a single-center tertiary care academic hospital in Wuhan, Hubei, China, between February 4, 2020, and follow-up to April 14, 2020. A total of 2899 patients with COVID-19 were included as participants in this study, and they were divided into five groups based on hepatitis B infection status. Fo

SUBMITTER: Yang S 

PROVIDER: S-EPMC9038996 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature